Allergy Therapeutics plc has disclosed a public dealing disclosure by an exempt principal trader, Panmure Gordon (UK) Limited, in accordance with Rule 8.5 of the Takeover Code. The disclosure relates to the trading activities of Panmure Gordon in relation to Allergy Therapeutics plc's relevant securities. The dealings were undertaken on August 23, 2023.

In terms of purchases and sales, Panmure Gordon purchased 9,683 securities of Allergy Therapeutics at a highest price per unit of 0.024444 and a lowest price per unit of 0.024444. They also sold 3,327 securities at a price per unit of 0.026.

No cash-settled derivative transactions or stock-settled derivative transactions were reported in the disclosure.

The disclosure does not include any details of indemnity or option arrangements, agreements, arrangements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing.

The contact person for the disclosure is Freddie Wooding, and the telephone number provided is +44 (0)20 7886 2969.

This disclosure is made in accordance with the Code's dealing disclosure requirements and must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation regarding the Code's requirements.